Movement Alert｜Ascentage Pharma Rises 6.35% in Regular Trading, B-Marker Removal Milestone Combined with ASCO Catalysts

Market Focus

05/29

On May 29, Ascentage Pharma rose 6.35% in regular trading, trading at 39.96 HKD/share, with trading volume of approximately 43.18 million HKD.

The rally was driven by a dual catalyst. The company received approval from the Hong Kong Stock Exchange to remove the B marker from its stock code effective June 1, after meeting the market capitalization and revenue requirements under Listing Rule 8.05. The milestone was underpinned by its core products Nerlynx (olverembatinib) and lisaftoclax generating over 500 million HKD in revenue. Historically, 18A companies that achieved B-marker removal have seen meaningful valuation re-rating.

Simultaneously, the ASCO Annual Meeting officially opened on May 29, with six of the company's clinical studies selected for presentation, including three rapid oral reports covering olverembatinib, lisaftoclax, and alrizomadlin. Financial results for the prior year showed revenue of 574 million RMB, with market capitalization exceeding 10 billion HKD.

Within the Biotechnology sector, broad strength was evident. Among individual stocks, Innovent Biologics up 10.29%, Akeso up 7.25%, 3SBio up 4.99%, RemeGen up 3.23%, BeiGene up 1.54%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1188168589"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1188168589\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1188168589?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 11:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188168589","market":"us","top_or_hot":-1,"title":"Movement Alert｜Ascentage Pharma Rises 6.35% in Regular Trading, B-Marker Removal Milestone Combined with ASCO Catalysts","media":"Market Focus","content":"<p><p>On May 29, Ascentage Pharma rose 6.35% in regular trading, trading at 39.96 HKD/share, with trading volume of approximately 43.18 million HKD.</p><p>The rally was driven by a dual catalyst. The company received approval from the Hong Kong Stock Exchange to remove the B marker from its stock code effective June 1, after meeting the market capitalization and revenue requirements under Listing Rule 8.05. The milestone was underpinned by its core products Nerlynx (olverembatinib) and lisaftoclax generating over 500 million HKD in revenue. Historically, 18A companies that achieved B-marker removal have seen meaningful valuation re-rating.</p><p>Simultaneously, the ASCO Annual Meeting officially opened on May 29, with six of the company's clinical studies selected for presentation, including three rapid oral reports covering olverembatinib, lisaftoclax, and alrizomadlin. Financial results for the prior year showed revenue of 574 million RMB, with market capitalization exceeding 10 billion HKD.</p><p>Within the Biotechnology sector, broad strength was evident. Among individual stocks, Innovent Biologics up 10.29%, Akeso up 7.25%, 3SBio up 4.99%, RemeGen up 3.23%, BeiGene up 1.54%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Ascentage Pharma Rises 6.35% in Regular Trading, B-Marker Removal Milestone Combined with ASCO Catalysts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Ascentage Pharma Rises 6.35% in Regular Trading, B-Marker Removal Milestone Combined with ASCO Catalysts\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time smaller\">2026-05-29 11:50</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><p>On May 29, Ascentage Pharma rose 6.35% in regular trading, trading at 39.96 HKD/share, with trading volume of approximately 43.18 million HKD.</p><p>The rally was driven by a dual catalyst. The company received approval from the Hong Kong Stock Exchange to remove the B marker from its stock code effective June 1, after meeting the market capitalization and revenue requirements under Listing Rule 8.05. The milestone was underpinned by its core products Nerlynx (olverembatinib) and lisaftoclax generating over 500 million HKD in revenue. Historically, 18A companies that achieved B-marker removal have seen meaningful valuation re-rating.</p><p>Simultaneously, the ASCO Annual Meeting officially opened on May 29, with six of the company's clinical studies selected for presentation, including three rapid oral reports covering olverembatinib, lisaftoclax, and alrizomadlin. Financial results for the prior year showed revenue of 574 million RMB, with market capitalization exceeding 10 billion HKD.</p><p>Within the Biotechnology sector, broad strength was evident. Among individual stocks, Innovent Biologics up 10.29%, Akeso up 7.25%, 3SBio up 4.99%, RemeGen up 3.23%, BeiGene up 1.54%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06855","symbol_name":"亞盛醫藥","start_time":0,"source_url":"","article_id":"1188168589","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188168589","pubTimestamp":1780026619,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 29, Ascentage Pharma rose 6.35% in regular trading, trading at 39.96 HKD/share, with trading volume of approximately 43.18 million HKD.The rally was driven by a dual catalyst. The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06855":"亚盛医药"},"translate_title":"异动快讯|亚盛医药常规交易涨6.35%B标移除里程碑叠加ASCO催化剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06855":1},"content_text":"On May 29, Ascentage Pharma rose 6.35% in regular trading, trading at 39.96 HKD/share, with trading volume of approximately 43.18 million HKD.The rally was driven by a dual catalyst. The company received approval from the Hong Kong Stock Exchange to remove the B marker from its stock code effective June 1, after meeting the market capitalization and revenue requirements under Listing Rule 8.05. The milestone was underpinned by its core products Nerlynx (olverembatinib) and lisaftoclax generating over 500 million HKD in revenue. Historically, 18A companies that achieved B-marker removal have seen meaningful valuation re-rating.Simultaneously, the ASCO Annual Meeting officially opened on May 29, with six of the company's clinical studies selected for presentation, including three rapid oral reports covering olverembatinib, lisaftoclax, and alrizomadlin. Financial results for the prior year showed revenue of 574 million RMB, with market capitalization exceeding 10 billion HKD.Within the Biotechnology sector, broad strength was evident. Among individual stocks, Innovent Biologics up 10.29%, Akeso up 7.25%, 3SBio up 4.99%, RemeGen up 3.23%, BeiGene up 1.54%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}